Division Head and Professor of Molecular Pharmaceutics and Drug Delivery Dr. Bill Williams was on KXAN News to talk about promising new data from TFF Pharmaceuticals and Augmenta Bioworks. The companies plan to develop Dr. Williams' thin film freezing technology to better deliver antibody treatment directly to the lungs of COVID patients.
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.
Laura Cannon, Pharm.D., MPH, is an oncology pharmacist and clinical assistant professor at the UT College of Pharmacy. She was in her residency when her late husband was diagnosed with cancer. Her experience shapes her unique perspective as she works to simplify the education process surrounding cancer treatment.
Molecular Pharmaceutics and Drug Delivery Professor Robert O. (Bill) Williams III, Ph.D. talks to CBS Austin about the potential for his thin film freezing technology to increase the shelf life of COVID-19 vaccines when they become available.
It is with great sadness that we announce the passing of Edward (Ted) Mills, Ph.D., associate professor in the Division of Pharmacology and Toxicology and Bergen Brunswig Corporation Centennial Fellow.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.